Updated time: 2021-08-09 11:39:57
28A-1061213
2021-02-23
TW I734242、PCT pending
Surgery is the only curative treatment for early-stage non-small cell lung cancer (NSCLC) patients. However, approximately one-third of these patients develop recurrence, which remains the main cause of mortality in the postsurgical treatment of NSCLC. EFHD2 increases cell migration and invasion abilities and promotes the epithelial-to-mesenchymal transition character of lung adenocarcinoma cells. In clinical relevance, EFHD2 is significantly correlated with postsurgical recurrence of patients with early-stage lung adenocarcinoma in the Kaplan- Meier-plotter cancer database search and our retrospective cohort study (HR, 6.14; 95% CI, 2.40-15.74; P < 0.001). We claim that EFHD2 serves as a marker to predict postsurgical recurrence of patients with early-stage lung adenocarcinoma. EFHD2 can be used to predict the postsurgical recurrence of patients with early-stage lung adenocarcinoma, esophageal squamous cell carcinoma, and clear cell renal cell carcinoma. Currently, several clinical and pathologic parameters have been proposed to distinguish those patients at increased risk of recurrence, but whether these screening parameters improve the survival outcome of patient remains elusive. To date, no molecular marker is applied into the clinic.
- The present invention exhibited overexpression in all highly metastatic tumor cell lines.
- The protein is detected from the blood, with a simple, economical, rapid, non-invasive painless easy to accept features.
- The present invention has sensitivity and specificity than previous markers.
- The present invention could serve as an independent marker to predict postsurgical recurrence of patients with stage I lung adenocarcinoma.
Chung-Hsuan Chen, Wei-Chao Chang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

EFHD2 serves as a marker to predict postsurgical recurrence of patients with early stage lung adenocarcinoma